BMS-955176

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
BMS-955176
BMS-955176.svg
Legal status
Legal status
  • Investigational
Identifiers
ChemSpider
Chemical and physical data
Formula C42H62N2O4S
Molar mass 691.03 g·mol−1
3D model (JSmol)

BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.[1] First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been selected to better tolerate gag polymorphisms.[2][3]

Studies[edit]

Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).[4] Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.[4][5] Phase 2b studies are currently ongoing in early 2016.[6][7] It appears that development of BMS-955176 has been terminated. [8]

References[edit]